When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...
Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...
DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to ...
DexCom has had a rough ride this year. The medical technology company is grappling with concerns about its slowing growth and allegations of faulty blood glucose monitors. However, DexCom is “already ...
Continuous glucose monitoring may have a role in identifying and preventing diabetes among healthy adults, but more studies ...
The GRACE trial suggests that real time continuous monitoring can reduce the risk of having a larger baby in women with gestational diabetes without increasing serious complications, although the ...
Rarer diabetes patients in Singapore can now receive up to 80% government subsidies for continuous glucose monitoring (CGM) ...
Discover why DexCom (DXCM) could rebound in 2025. Explore buyback plans, growth potential, and investment insights in the ...
Real-time continuous glucose monitoring (rt-CGM) reduced large-for-gestational-age (LGA) births in women with gestational diabetes.
A continuous glucose monitor (CGM) can tell you when my glucose spikes, but not that I delayed correcting it because I was in a high-stakes meeting. It can record the number after I under-bolused for ...
MiniMed is pitching the breadth of its portfolio as an advantage over more focused rivals such as Dexcom and Insulet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback